Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biofrontera AGLTS:0DOL 16 Receivables Turnover is 0.79 as of Mar. 2026. GuruFocus rates LTS:0DOL with a GF Score™ of 16/100 and a GF Value™ of €2.41 (Fairly Valued). The stock has 4 warning signs investors should review. Among 948 Drug Manufacturers companies, Biofrontera AG ranks worse than 74.26% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Biofrontera AG's Revenue for the
three
months ended in Mar. 2026 was €3.71 Mil. Biofrontera AG's average Accounts Receivable for the
three
months ended in Mar. 2026 was €4.70 Mil.
Hence, Biofrontera AG's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.79.
Biofrontera AG (LTS:0DOL) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Biofrontera AG Receivables Turnover Related Terms
Biofrontera AG Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Biofrontera AG's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DOL vs ZTS, UTHR, VTRS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera AG Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Biofrontera AG's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofrontera AG (LTS:0DOL) has a Receivables Turnover of 0.79 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Biofrontera AG and its competitors. According to the industry distribution chart, Biofrontera AG ranks #704 out of 948 companies in the Drug Manufacturers industry, placing it in the top 74.3%.
Is Biofrontera AG's Receivables Turnover too high?
Biofrontera AG's current Receivables Turnover is 0.79. The Drug Manufacturers industry median Receivables Turnover is 5.07. Biofrontera AG's value of 0.79 is 84.4% below this industry median. Based on the distribution chart, Biofrontera AG ranks #704 out of 948 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Biofrontera AG has a GF Score™ of 16/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofrontera AG ranks #704 out of 948 companies for Receivables Turnover. This places Biofrontera AG in the lower half of its industry. The industry median Receivables Turnover is 5.07. Biofrontera AG's value of 0.79 is 84.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofrontera AG's current Receivables Turnover of 0.79 is 84.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Biofrontera AG and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofrontera AG's current Receivables Turnover is 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Based on GuruFocus' analysis, Biofrontera AG (LTS:0DOL) is currently considered Fairly Valued. The stock's GF Value™ is €2.41, compared to a current price of €2.27 — trading 5.8% below its estimated fair value. The current Receivables Turnover is 0.79 and 84.4% below the Drug Manufacturers industry median of 5.07. Biofrontera AG's overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Biofrontera AG (LTS:0DOL), the current Receivables Turnover is 0.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofrontera AG (LTS:0DOL) Overvalued in 2026?
Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued.
The current stock price of €2.27 is trading 5.8% below its estimated GF Value™ of €2.41.
GuruFocus considers Biofrontera AG to be Fairly Valued.
Key valuation signals for LTS:0DOL:
Receivables Turnover: 0.79
GF Value™: €2.41 vs. price of €2.27 (5.8% below fair value)
Industry Position: 84.4% below the Drug Manufacturers median (#704 of 948)
No single metric tells the full story. See the LTS:0DOL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
16GF Score
Get the complete analysis for LTS:0DOL
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DOL has been successfully added to your 
